EM2, page-4

Here's to hoping it has because at the moment it feels like a pump and dump that has been played over a number of years. It only feels like this though, as I do believe there really is a great asset here that can work. Actually the chart looks like it too.

But it's not like a lithium junior spruiking lepidolite as the next big thing in lithium deposits. Here we have the right ore, the right studies, the asset exists, the funding is a very tough part of the game.

It would be interesting to see if the directors that bought shares en masse in March 2021 are still holding or if they are the ones that have slowly sold off their holdings to bring the stock to its current levels.

Glycine is essential for building muscles and connective tissue, so perhaps it will bulk up the stock price with some mad guns to flex when used in the processing.